You are here

A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Poway, California, 92064 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Lung Neoplasms
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- presence of measurable, metastatic non-small cell lung cancer (histologically or
cytologically confirmed at the time of original diagnosis)

- treatment failure (recurrence, disease progression, or intolerable toxicity) of 2 or 3
prior systemic treatments. (Note: no more than 3 prior systemic regimens for non-small
cell lung cancer including adjuvant chemotherapy)

- capable of understanding the nature of the trial and willing to give written informed
consent

- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2

- hemoglobin level of >=9 g/dL, absolute granulocyte count of >=1.5 × 109/L, and
platelet count of >=100 × 109/L

- adequate renal function, as documented by a serum creatinine level of institutional upper limit of normal (ULN) and a measured or calculated creatinine
clearance of >=60 mL/min

- adequate liver function, as demonstrated by a total bilirubin level of ULN; levels of serum glutamate oxaloacetic transaminase (SGOT) (aspartate
aminotransferase [AST]) and serum glutamate pyruvate transaminase (SGPT) (alanine
aminotransferase [ALT]) and ALT should be

- for men with partners of child-bearing potential and all women of childbearing
potential, willingness to use adequate contraception or practice abstinence during the
course of the study at least 18 years of age

- life expectancy estimated at greater than 12 weeks

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- history of blood transfusion within the last 14 days

- need of concurrent administration of allopurinol

- history of radiotherapy or chemotherapy within 4 weeks (nitrosourea or mitomycin C
within 6 weeks) of the anticipated first day of dosing (patient must be fully
recovered from the acute effects of any prior chemotherapy or radiotherapy)

- any psychological or sociological condition, addictive disorder, or family problems
that might preclude compliance with the protocol

- any unstable or severe intercurrent medical condition that in the opinion of the
investigator might interfere with achievement of study objectives

- receipt of an investigational agent within 28 days before the anticipated first day of
dosing (patient must have recovered from all acute effects of previously administered
investigational agents)

- pregnant or breast-feeding

- previous treatment with GARFT inhibitors

- history of radiation therapy to more than 40% of the marrow space

- history of a malignancy (other than non-small cell lung cancer) except those treated
with curative intent for skin cancer (other than melanoma) or in situ breast or
cervical cancer or those treated with curative intent for any other cancer with no
evidence of disease for 5 years

- active brain metastases (requiring treatment or progressing)

NCT00090701
Pfizer
Withdrawn
A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now